• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Structure . Structural basis of nanobodies neutralizing SARS-CoV-2 variants

tetano

Editor, Senior Moderator
Structure


. 2022 Mar 1;S0969-2126(22)00047-8.
doi: 10.1016/j.str.2022.02.011. Online ahead of print.
Structural basis of nanobodies neutralizing SARS-CoV-2 variants


Zhenzhong Shi[SUP] 1 [/SUP], Xiyang Li[SUP] 2 [/SUP], Lu Wang[SUP] 3 [/SUP], Zengchao Sun[SUP] 1 [/SUP], Haiwei Zhang[SUP] 4 [/SUP], Xiaochen Chen[SUP] 3 [/SUP], Qianqian Cui[SUP] 5 [/SUP], Huarui Qiao[SUP] 6 [/SUP], Zhongyun Lan[SUP] 6 [/SUP], Xin Zhang[SUP] 6 [/SUP], Xianheng Li[SUP] 6 [/SUP], Lingyun Li[SUP] 3 [/SUP], Jianfeng Xu[SUP] 7 [/SUP], Rui Gong[SUP] 8 [/SUP], Chengpeng Fan[SUP] 9 [/SUP], Yong Geng[SUP] 10 [/SUP]



Affiliations

Abstract

Because of the evolutionary variants of SARS-CoV-2, development of broad-spectrum neutralizing antibodies resilient to virus escape is urgently needed. We identified a group of high-affinity nanobodies from camels immunized with receptor-binding domain (RBD) of SARS-CoV-2 spike protein and resolved the structures of two non-competing nanobodies (NB1A7 and NB1B11) in complex with RBD using X-ray crystallography. The structures show that NB1A7 targets the highly conserved cryptic epitope shared by SARS-CoV-2 variants and some other coronaviruses and blocks ACE2 receptor attachment of the spike protein, and NB1B11 epitope overlaps with the contacting surface of ACE2 and is different from the binding site of NB1A7. These two nanobodies were covalently linked into multivalent and bi-paratopic formats, which significantly improved the avidity and neutralization potency and may further inhibit viral escape. The results contribute to the structure-guided design of antibodies against future variants of SARS-CoV-2 virus to combat coronavirus epidemics and pandemics.

Keywords: SARS-CoV-2 virus; bi-paratopic nanobodies; crystal structure; nanobody; receptor-binding domain.
 
Back
Top Bottom